AI news ·
Sequential raises $3.5M to build AI discovery platform for skin health ingredients
Sequential raised $3.5M in its first equity round, bringing total funding to $7.5M. The company uses AI and a dataset of 50,000+ skin samples to predict ingredient combinations for personal care products.
Sequential Raises $3.5M for AI-Powered Skin Health Discovery Platform
Sequential, a genomic testing company, closed its first equity round with $3.5 million in funding. The round was co-led by Sparkfood and Corundum Systems Biology, with backing from Dermazone Holdings, SOSV, Scrum Ventures, and an ex-General Partner at Index Ventures. The company has now raised $7.5 million total.
The funding will support development of an AI discovery engine built on Sequential's clinical dataset of over 50,000 skin samples, 4,000+ ingredients tested, and 10,000+ participants. The platform aims to predict and optimize next-generation active ingredient combinations for personal care products.
What Sequential Does
Sequential uses non-invasive testing to measure how ingredients and consumer products alter microbial and host biomarkers on human skin. The company translates complex biological data into actionable insights by combining microbial and molecular analyses.
The approach differs from traditional formulation work. Instead of incremental improvements to existing products, Sequential's AI engine systematically designs and validates new ingredient combinations based on real clinical data.
Why This Matters for Product Development
Product developers typically rely on limited testing data or historical formulation patterns. Sequential's dataset represents one of the largest clinical collections in dermatological health, giving companies access to evidence on how specific ingredients perform in real-world conditions.
Anouk Veber, Ventures' Business Unit Leader at Sparkfood, said the company has "built a unique bridge between biology, clinical validation, and consumer product development." Hidehiko Otake, CEO of Corundum Systems Biology, added that Sequential's approach aligns with using "large datasets, the microbiome, and artificial intelligence" to transform health outcomes.
Sequential operates labs in Cambridge, England; New York City; and Singapore. The company was previously supported by Innovate UK and Enterprise Singapore.
For product developers looking to incorporate AI for Product Development or AI for Science & Research, Sequential's approach demonstrates how machine learning applies to ingredient discovery and validation in consumer health.